Epidemiological and clinical features of asymptomatic patients with SARS-CoV-2 infection

Few studies reported the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients with completely asymptomatic throughout the disease course. We investigated the epidemiological and clinical features of patients infected by SARS-CoV-2 without any symptoms. Patients with confirmed SARS-CoV-2 infection were retrospectively recruited. The demographic characteristics, clinical data, treatment, and outcomes of SARS-CoV-2 infected patients without any symptoms were analyzed. Fifteen (4.4%) of 342 SARS-CoV-2 infected patients did not develop any symptom during the course of the disease. The median time from exposure to diagnosis was 7.0 days (interquartile range [IQR]: 1.0-15.0 days). Of the 15 patients, 14 patients were diagnosed by tested positive for SARS-CoV-2 in throat swabs, while one patient was only tested positive for SARS-CoV-2 in anal swabs. During hospitalization, only 1 (6.7%) patient developed lymphopenia. Abnormalities of chest computed tomography examinations were detected in 8 (53.4%) patients on admission. As of 8 March 2020, all patients have been discharged. The median time of SARS-CoV-2 tested negative from admission was 7.0 days (IQR: 4.0-9.0 days). Patients without any symptoms but with SARS-CoV-2 exposure should be closely monitored and tested for SARS-CoV-2 both in anal and throat swabs to excluded the infection. Asymptomatic patients infected by SARS-CoV-2 have favorable outcomes.     

Controlled and Targeted Drug Delivery by a UV‐responsive Liposome for Overcoming Chemo‐resistance in Non‐Hodgkin Lymphoma

Although chemotherapy plays a vital role in treating non‐Hodgkin lymphomas, the clinical applications are limited because of intolerable side‐effects and multidrug resistance at the beginning or during the course of therapy. In this study, we successfully fabricated a CD20‐targeting immuno‐liposome based on 1,2‐bis(10,12‐tricosadiynoyl)‐sn‐glycero‐3‐phosphocholine (DC‐8,9PC), which can form intermolecular cross‐linking through the diacetylenic group by ultraviolet irradiation. This immuno‐liposome showed appropriate size distribution, well‐defined regular spherical structure, favorable biocompatibility, high serum stability, and prolonged circulation time in blood vessels. The in and ex vivo experiments demonstrate enhanced tumor suppression abilities against both wild‐type and resistant non‐Hodgkin lymphomas for liposomal doxorubicin when compared with free drugs. The outstanding antitumor activities are attributed to the accumulation and retention of liposomal drugs in malignant tissues and cells, which are realized by the co‐operation of active targeting via antibody–antigen reaction and passive targeting via enhanced permeability and retention effect.     

lncRNA MEG3 基因多态性与不同宫颈病变的相关性研究

目的:探讨MEG3 rs10132552 和rs7158663单核苷酸多态性（single nucleotide polymorphism，SNP）与不同宫颈病变患者发病风险的关系。方法:2018年11月到2020年11月，收集328例宫颈病变患者的外周静脉血及相关临床信息为病例，包括210例宫颈上皮内病变（cervical intraepithelial neoplasia，CIN）患者和118例宫颈癌（cervical cancer,CC）患者，以同期住院的345例无宫颈病变患者作为对照组，采用TaqMan RT-PCR方法进行基因分型，采用χ2检验和logistic 回归分析SNP位点与不同级别宫颈病变的相关性。结果:与对照组相比，MEG3 rs10132552 CT+CC基因型在宫颈病变组中分布频率显著降低（P＜0.05），其发病风险为0.701（95%CI:0.515~0.954）；且在>50岁患者中，携带MEG3 rs10132552 CT+CC基因型发生宫颈病变的风险显著降低(OR=0.634，95%CI:0.412~0.978,P＜0.05)。将宫颈病变组分为宫颈上皮内病变组和宫颈癌组进行分层分析发现，该位点CT+CC基因型主要降低了宫颈癌组的发病风险（OR=0.520，95%CI:0.333~0.811，P＜0.05)；进一步进行临床进展相关性分析，未发现MEG3 rs10132552与不同级别宫颈上皮内病变、不同病理类型、临床分期的宫颈癌具有相关性(P＞0.05)。未发现MEG3 rs7158663位点与不同级别宫颈病变具有相关性(P＞0.05)。结论:MEG3 rs10132552 SNP与宫颈癌的发病风险相关，其CT+CC基因型可能是宫颈癌发生的保护因素。     

不同下颌骨截骨方式在咽相关区域肿瘤手术中的应用

目的 探讨不同下颌骨截骨方式在咽相关区域暴露及肿瘤切除手术中的适应证.方法 回顾性分析2006年1月至2013年12月采用下颌骨截骨方式切除咽相关解剖区域肿瘤23例,其中应用下颌骨正中截开7例,下颌骨角部截开6 例,单纯下颌骨方块或“L”型截骨5例,下颌骨升支纵行截开5例.结果 运用4种下颌骨截骨方式,术野暴露满意,均完整切除肿瘤,恶性肿瘤切缘均为阴性;12例患者术后给予放疗或同步放化疗,均未出现放射性骨髓炎.所有患者术后下颌功能恢复良好,张口度及咬合达到理想要求.结论 咽相关区域复杂肿瘤手术时根据肿瘤原发位置、性质及大小,灵活机动地采取不同的下颌骨截骨方式,不仅可以获得良好的术野和肿瘤切除的安全界限,也可以较好地满足一期修复及口颌系统功能恢复的要求.     

不同级别子宫颈病变与lncRNA HOTTIP和H19单核苷酸多态性的关系研究

背景与目的:HOTTIP和H19都是lncRNA(long non-coding RNA,lncRNA)中的一员,在肿瘤的发生、发展和迁移过程中发挥重要作用.本研究探讨HOTTIP rs2067087、H19 rs2839698和H19 rs2107425单核苷酸多态性(single nucleotide polymo...     

Novel reduction‐sensitive micellar nanoparticles assembled from Rituximab–doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non‐Hodgkin's lymphoma

In this study, a novel reduction‐sensitive drug delivery system, the rituximab–doxorubicin (RTX‐DOX) micellar nanoparticle (RDMN), was specially designed for targeted delivery and release of DOX in non‐Hodgkin's lymphoma (NHL) cells. The RDMN was fabricated by self‐assembling of amphiphilic RTX‐DOX conjugates (RDCs), which were synthesized by conjugating the hydrophilic Fab fragments of RTX (an anti‐CD20 monoclonal antibody) and hydrophobic DOXs by a reduction‐responsive linker, 3‐(2‐Pyridyldithio) propionyl hydrazide (PDPH). The RDMNs were characterized via dynamic light scattering and transmission electron microscopy, both showed the sizes of approximately 94.1 ± 14.5 nm with a uniform size distribution. Polyplex dissociation, which was indicated by accelerated DOX release rate and increased particle size, was observed in the presence of 2.5 mm 1,4‐dithiothreitol due to the cleavage of disulfide bonds in PDPH linkers. In vitro transfection assays against human NHL cell line, JeKo‐1, showed significantly increased uptake for RDMNs, as compared to RDCs and free RTX/DOX. Both in and ex vivo experiments demonstrated that RDMNs showed the highest therapeutic effect among all the experimental groups. These results suggested that this RDMN could be a potential, safe and efficient drug delivery vector, which deserves further investigation in the clinic.     

胃癌中B7-H4和B7-H3的表达及薏苡仁酯对表达的影响

目的:探讨共刺激分子B7-H4和B7-H3在胃癌中的表达,以及薏苡仁酯对这两种分子表达的影响。方法:应用免疫组织化学染色检测胃癌组织中B7-H4蛋白的表达,MTT法检测薏苡仁酯对胃癌细胞株BGC-823的生长抑制效应,RT-PCR检测胃癌组织、胃癌细胞株BGC-823中B7-H4mRNA及B7-H3mRNA的表达,Western Blot检测细胞的B7-H4蛋白及B7-H3蛋白的表达。结果:B7-H4蛋白在80例胃癌组织中有60例阳性表达,阳性率75%。B7-H4蛋白的表达与患者性别、年龄、组织类型、肿瘤大小、淋巴结转移、病理分期、浸润深度无关(P>0.05)。在20例胃癌组织中,B7-H4mRNA表达明显高于癌旁正常组织,B7-H3mRNA表达明显低于癌旁正常组织(P<0.01)。薏苡仁酯可抑制胃癌细胞株BGC-823的生长,呈时间-剂量依赖性,并下调B7-H4 mRNA及蛋白的表达,上调B7-H3mRNA及蛋白的表达(P<0.01)。结论:B7-H4和B7-H3在胃癌异常的表达,可能是肿瘤免疫逃逸的原因之一;薏苡仁酯可影响胃癌细胞B7-H4、B7-H3的表达。